Support Grows for SEC Proposal to Replace Quarterly Reporting with Semiannual Reporting

A comment letter from several pharmaceutical companies, including Eli Lilly and Co., has been submitted in support of the Securities and Exchange Commission's (SEC) proposed rule to allow for optional semiannual reporting. Proponents argue this would reduce regulatory burden while investors would still receive timely, material information through other disclosures.